Travere Therapeutics

Quarterly Financials

Values in thousands2025-12-312025-09-302025-06-302025-03-31
Revenue
$129,689
$164,859
$114,449
$81,732
Gross Profit
108,999
163,274
112,928
77,053
EBITDA
-632
44,253
4,127
-25,528
EBIT
-18,769
28,465
-9,889
-38,330
Net Income
-21,986
25,706
-12,755
-41,226
Net Change In Cash
129,689
164,859
114,449
81,732
Free Cash Flow
61,053
14,177
4,748
-53,978
Cash
93,035
110,930
75,154
61,897
Basic Shares
90,293
102,618
88,946
88,356

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$490,728
$233,175
$145,238
$109,460
Gross Profit
419,646
225,431
133,788
105,040
EBITDA
22,218
-265,773
-326,246
-299,422
EBIT
-38,525
-309,328
-364,776
-320,141
Net Income
-50,261
-321,545
-111,399
-278,482
Net Change In Cash
490,728
233,175
145,238
109,460
Cost of Revenue
-101,271
Free Cash Flow
37,784
-338,687
-321,612
-214,657
Cash
93,035
58,535
58,176
61,688
Basic Shares
89,211
78,889
74,267
63,758

Earnings Calls

QuarterEPS
2025-12-31
$0.37
2025-09-30
$0.59
2025-06-30
$0.13
2025-03-31
-$0.19